Key Highlights

  • Second-quarter revenue reached $1.00 billion, above the consensus estimate of approximately $977 to $980 million, despite declining 2.7% year over year.
  • Non-GAAP earnings per share came in at $3.02, more than 10% above the estimated $2.74, up 47% sequentially.
  • Organic revenue growth turned positive at 0.1%, the company's strongest pace since the third quarter of 2023.
  • Full-year 2026 non-GAAP earnings per share guidance was raised to $11.15 to $11.45, from a prior $10.80 to $11.30.

A Meaningful Inflection Point in Organic Growth

Charles River Laboratories International, Inc. (NYSE:CRL) reported second-quarter revenue of $1.00 billion, above the $977 to $980 million consensus estimate, even as revenue declined 2.7% year over year due to recent portfolio divestitures. Organic revenue growth turned positive at 0.1%, the company's strongest pace since the third quarter of 2023 and a notable inflection point after an extended period of demand softness across the contract research organization industry.

Non-GAAP earnings per share of $3.02 topped the estimated $2.74 by more than 10%, up 47% sequentially, with operating margin rising 420 basis points sequentially to 20.5%, driven by divestiture benefits and easing margin headwinds.

Discovery Services Momentum Signals Improving Biotech Demand

The Discovery and Safety Assessment segment showed particularly strong momentum, with net bookings up 12.6% sequentially to $701 million, bringing backlog to $1.97 billion and a net book-to-bill ratio of 1.19, the highest level in nearly four years and the third consecutive quarter above 1.0. Segment organic revenue grew 0.2%, also its first growth since the third quarter of 2023, a signal management pointed to as evidence of improving biotech and pharmaceutical client demand following a prolonged industry downturn.

The company raised its full-year Discovery and Safety Assessment revenue outlook to low single digit organic growth, reflecting this improving momentum. Manufacturing Solutions performance also came in stronger than expected, while Research Models and Services and North American academic and government demand remained comparatively soft, an area management attributed to flat NIH budget levels affecting academic research funding.

The company completed divestitures of its European Discovery Services sites, contract development and manufacturing organization business, and Cell Solutions businesses in May, driving manufacturing segment margin to 37.8% in the second quarter, with expectations to approach 40% in the second half.

Guidance Raise Reflects Confidence in Sustained Improvement

Management raised full-year 2026 guidance, with organic revenue growth now expected flat to up 1%, a 150 basis point improvement from prior guidance, while reported revenue is now expected to decline 2.5% to 3.5% due to the divestiture impact, an improvement from the previously guided 4% to 6% decline. Operating margin expansion guidance of approximately 120 to 150 basis points was introduced, with free cash flow guidance raised to $400 million to $420 million from a prior $375 million to $400 million.

Some factors could support continued momentum. Approximately 500 basis points of margin improvement is expected in the second half compared to the first half, with roughly half attributable to completed portfolio actions and about 150 basis points from lower corporate costs, alongside benefits from lower non-human primate sourcing costs tied to a recent Cambodia acquisition. Conversely, continued softness in North American academic and government demand, tied to flat NIH budget levels, could persist as a headwind independent of improving biotech and pharma client trends.

The results arrived alongside a mixed broader diagnostics and life sciences earnings backdrop, suggesting the improving demand reflected in Charles River's results may be part of a broader, if uneven, stabilization following a prolonged funding downturn.

Conclusion

Charles River Laboratories' second quarter marked a meaningful inflection point, with organic revenue growth turning positive for the first time since 2023 and a substantial earnings beat prompting a guidance raise. The durability of this recovery is likely to depend on whether strong bookings momentum in Discovery and Safety Assessment continues translating into sustained revenue growth, even as softer North American academic demand tied to flat NIH funding remains a headwind.